Gossamer Bio (GOSS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 25, 2025, to be held virtually, with registration required by June 24, 2025.
Four key proposals: election of three Class I directors, ratification of Ernst & Young LLP as auditor, advisory vote on executive compensation, and approval of amended 2019 Incentive Award Plan.
Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Election of three Class I directors for three-year terms expiring in 2028.
Ratification of Ernst & Young LLP as independent auditor for 2025.
Advisory vote on executive compensation (say-on-pay).
Approval of amendment and restatement of the 2019 Incentive Award Plan, including an increase of 11,350,000 shares and extension of the plan term to 2035.
Shareholder proposals for the 2026 meeting must be received by December 30, 2025.
Board of directors and corporate governance
Board consists of seven members, with a majority deemed independent under Nasdaq rules.
Board leadership includes a combined Chairman/CEO and a lead independent director.
Three standing committees: audit, compensation, and nominating/corporate governance, all with independent members.
Annual review of board composition and director qualifications, with a focus on diversity and relevant expertise.
Non-employee director compensation program updated in February 2025 to increase committee retainers.
Latest events from Gossamer Bio
- Seralutinib showed promise in subgroups but missed its primary endpoint, triggering strategic shifts.GOSS
Q4 202517 Mar 2026 - Seralutinib improved exercise capacity and biomarkers in high-risk PAH, with manageable safety.GOSS
Study result23 Feb 2026 - Seralutinib advances in global phase III trials, with Chiesi partnership accelerating PH-ILD expansion.GOSS
Presents at Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Seralutinib's phase III trials progress with strong data, global reach, and robust financial backing.GOSS
Guggenheim Securities Inaugural Healthcare Innovation Conference15 Jan 2026 - PROSERA nears enrollment completion, with Q4 data and commercial launch plans progressing.GOSS
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Seralutinib targets late-stage PAH and PH-ILD markets with best-in-class safety and strong commercial prospects.GOSS
Barclays 27th Annual Global Healthcare Conference 202526 Dec 2025 - Seralutinib advances in phase III with best-in-class safety, efficacy, and global reach.GOSS
Leerink’s Global Healthcare Conference 202526 Dec 2025 - Seralutinib’s phase III data in PH, expected late 2024, could reshape the treatment landscape.GOSS
Emerging Growth Conference 7923 Dec 2025 - Virtual annual meeting to vote on directors, auditor, pay, and incentive plan approval.GOSS
Proxy Filing2 Dec 2025